EUVIMEDEUVIMED entdecken
Open Access

Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II

Binh Y Nguyen iD, Fangchao Zhou, Pablo Binder iD, Wei Liu iD, Susanne S Hille iD, Xiaojing Luo iD, Min Zi iD, Hongyuan Zhang iD, Antony Adamson iD, Fozia Z Ahmed iD, Sam Butterworth, Elizabeth J Cartwright iD und 4 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Binh Y Nguyen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology, Medicine and Health The University of Manchester Manchester United Kingdom. Hauptthemen laut MEDLINE: Angiotensin II, Hypertension. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prolonged activation of angiotensin II is the main mediator that contributes to the development of heart diseases, so converting angiotensin II into angiotensin 1‐7 has emerged as a new strategy to attenuate detrimental effects of angiotensin II. Prolylcarboxypeptidase is a lysosomal pro‐X carboxypeptidase that is able to cleave angiotensin II at a preferential acidic pH optimum. However, insufficient attention has been given to the cardioprotective functions of prolylcarboxylpeptidase. Methods and Results We established a CRISPR/CRISPR‐associated protein 9–mediated global prolylcarboxylpeptidase‐knockout and adeno‐associated virus serotype 9–mediated cardiac prolylcarboxylpeptidase overexpression mouse models, which were challenged with the angiotensin II infusion (2 mg/kg per day) for 4 weeks, aiming to investigate the cardioprotective effect of prolylcarboxylpeptidase against hypertensive cardiac hypertrophy. Prolylcarboxylpeptidase expression was upregulated after 2 weeks of angiotensin II infusion and then became downregulated afterward in wild‐type mouse myocardium, suggesting its compensatory function against angiotensin II stress. Moreover, angiotensin II–treated prolylcarboxylpeptidase‐knockout mice showed aggravated cardiac remodeling and dampened cardiac contractility independent of hypertension. We also found that prolylcarboxylpeptidase localizes in cardiomyocyte lysosomes, and loss of prolylcarboxylpeptidase led to excessive angiotensin II levels in myocardial tissue. Further screening demonstrated that hypertrophic prolylcarboxylpeptidase‐knockout hearts showed upregulated extracellular signal‐regulated kinases 1/2 and downregulated protein kinase B activities. Importantly, adeno‐associated virus serotype 9–mediated restoration of prolylcarboxylpeptidase expression in prolylcarboxylpeptidase‐knockout hearts alleviated angiotensin II–induced hypertrophy, fibrosis, and cell death. Interestingly, the combination of adeno‐associated virus serotype 9–mediated prolylcarboxylpeptidase overexpression and an antihypertensive drug, losartan, likely conferred more effective protection than a single treatment protocol to mitigate angiotensin II–induced cardiac dysfunction.

Conclusions

Our data demonstrate that prolylcarboxylpeptidase protects the heart from angiotensin II–induced hypertrophic remodeling by controlling myocardial angiotensin II levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin IIHypertensionMiceAnimalsVentricular RemodelingMyocardiumMyocytes, CardiacMice, KnockoutFibrosisMice, Inbred C57BLCarboxypeptidases

Stichwörter der Autor:innen

hypertensionhypertrophylysosomeprolylcarboxylpeptidase

Substanzen

Angiotensin IIlysosomal Pro-X carboxypeptidaseCarboxypeptidases

Autor:innen und Institutionen

  • Faculty of Biology, Medicine and Health The University of Manchester Manchester United Kingdom.
  • Department of Internal Medicine III University of Kiel Kiel Germany.
  • Institute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus Technische Universitaet Dresden Dresden Germany.

ORCID-Profile: Binh Y Nguyen, Pablo Binder, Wei Liu, Susanne S Hille, Xiaojing Luo, Min Zi, Hongyuan Zhang, Antony Adamson, Fozia Z Ahmed, Elizabeth J Cartwright, Oliver J Müller, Kaomei Guan, Xin Wang

Förderung

  • British Heart Foundation

Zitieren

APA

Nguyen, B. Y., Zhou, F., Binder, P., Liu, W., Hille, S. S., Luo, X., Zi, M., Zhang, H., Adamson, A., Ahmed, F. Z., Butterworth, S., Cartwright, E. J., Müller, O. J., Guan, K., Fitzgerald, E. M., & Wang, X. (2023). Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028298

Vancouver

Nguyen BY, Zhou F, Binder P, Liu W, Hille SS, Luo X, et al. Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028298

BibTeX
@article{Nguyen2023,
  author = {Nguyen, Binh Y and Zhou, Fangchao and Binder, Pablo and Liu, Wei and Hille, Susanne S and Luo, Xiaojing and Zi, Min and Zhang, Hongyuan and Adamson, Antony and Ahmed, Fozia Z and Butterworth, Sam and Cartwright, Elizabeth J and Müller, Oliver J and Guan, Kaomei and Fitzgerald, Elizabeth M and Wang, Xin},
  title = {Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028298}
}
Kostenlos starten →